Skye Bioscience: Tang Capital reports 6% stake
The 6.0% ownership calculation is based on 4,427,676 SKYE common shares outstanding as of August 11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Skye Bioscience, Inc. (SKYE) is the issuer named in a Schedule 13G reporting 263,560 shares of common stock beneficially owned by Tang Capital Management, LLC and Kevin Tang, each with reported ownership of 6.0%. Both report shared voting and dispositive power over the same block, alongside Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc. The latter four entities report 60,000, 83,556, 60,002 and 60,002 shares, respectively. The ownership percentages are based on 4,427,676 common shares outstanding as of August 11, 2026. Kevin Tang is identified as manager of Tang Capital Management and chief executive officer of Tang Capital Partners III and Tang Capital Partners IV.
Key Figures
Key Terms
beneficially owned financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.